Monahan Rory C, Beaart Hannelore J L, Fronczek Rolf, Terwindt Gisela M, Beaart-van de Voorde Liesbeth J J, de Bresser Jeroen, Kloppenburg Margreet, van der Wee Nic J A, Huizinga Tom W J, Steup-Beekman Gerda M
Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, the Netherlands.
Department of Neurology, LUMC, Leiden, the Netherlands.
Neuropsychiatr Dis Treat. 2020 Dec 22;16:3173-3186. doi: 10.2147/NDT.S267000. eCollection 2020.
To evaluate the use of immunosuppressive treatment, clinical outcome and diagnostic strategy in patients with systemic lupus erythematosus (SLE) presenting with clinical features of transverse myelitis (TM), but normal MRI of the spinal cord (sMRI) and normal cerebrospinal fluid (CSF) assessment, and to suggest a clinical guideline.
All patients with SLE and clinical features compatible with (sub)acute TM visiting the NPSLE clinic of the LUMC between 2007 and 2020 were included. Information on baseline characteristics, investigations, treatment and outcomes was collected from electronic medical records. In addition, a systematic review of individual participant data was performed up to April 2020 in PubMed, Embase and Web of Science, identifying all patients with TM, SLE and sMRI assessment. Data regarding sMRI, CSF analysis, treatment and outcome were extracted, and outcome was compared between patients with normal sMRI and CSF (sMRI-/CSF-) and patients with abnormalities.
Twelve SLE patients with a clinical diagnosis of TM were identified: four sMRI-/CSF- and one sMRI- with CSF not available. All patients received immunosuppressive treatment, but outcome in sMRI-/CSF- patients was worse: no recovery (n=1) or partial recovery (n=3) compared to partial recovery (n=4) and (nearly) complete recovery (n=3) in MRI+ patients. The systematic literature review yielded 146 articles eligible for inclusion, 90% case reports. A total of 427 SLE patients with TM were identified, of which only four cases were sMRI-/CSF- (1%), showing no improvement (n=1), partial improvement (n=2) and complete recovery (n=1) after immunosuppressive treatment.
Outcome in SLE patients presenting with clinically suspected TM with normal sMRI and CSF is less favorable, despite treatment with immunosuppressive therapy. Taking a functional neurological disorder into consideration may be helpful in order to start other therapeutic strategies. We suggest prescribing immunosuppressive treatment for a restricted period of time to evaluate its effect in cases where a functional disorder initially is considered unlikely.
评估系统性红斑狼疮(SLE)患者出现横贯性脊髓炎(TM)临床特征,但脊髓MRI(sMRI)正常且脑脊液(CSF)评估正常时免疫抑制治疗的使用情况、临床结局及诊断策略,并提出临床指南。
纳入2007年至2020年期间就诊于LUMC的NPSLE诊所、具有与(亚)急性TM相符临床特征的所有SLE患者。从电子病历中收集基线特征、检查、治疗及结局的信息。此外,截至2020年4月在PubMed、Embase和Web of Science上对个体参与者数据进行系统综述,识别所有患有TM、SLE且进行了sMRI评估的患者。提取有关sMRI、CSF分析、治疗及结局的数据,并比较sMRI和CSF均正常(sMRI-/CSF-)的患者与存在异常的患者的结局。
确定了12例临床诊断为TM的SLE患者:4例sMRI-/CSF-,1例sMRI-且脑脊液情况未知。所有患者均接受了免疫抑制治疗,但sMRI-/CSF-患者的结局更差:无恢复(n = 1)或部分恢复(n = 3),而MRI+患者有部分恢复(n = 4)和(几乎)完全恢复(n = 3)。系统文献综述产生了146篇符合纳入标准的文章,90%为病例报告。共识别出427例患有TM的SLE患者,其中只有4例为sMRI-/CSF-(1%),免疫抑制治疗后无改善(n = 1)、部分改善(n = 2)和完全恢复(n = 1)。
对于临床上疑似TM但sMRI和CSF正常的SLE患者,尽管接受了免疫抑制治疗,结局仍不太理想。考虑功能性神经障碍可能有助于启动其他治疗策略。我们建议在最初认为不太可能是功能性障碍的情况下,在限定时间内给予免疫抑制治疗以评估其效果。